CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner-Reference-Cited by-同舟云学术

CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner

Published:2016-07-22 Issue:33 Volume:8 Page:54082-54095
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Abdelouahab Hadjer¹²³⁴,Zhang Yanyan¹³⁴,Wittner Monika¹³⁴,Oishi Shinya⁵,Fujii Nobutaka⁵,Besancenot Rodolphe¹³⁴,Plo Isabelle¹³⁴⁶⁷,Ribrag Vincent¹³⁴,Solary Eric¹³⁴,Vainchenker William¹³⁴⁷,Barosi Giovanni⁸,Louache Fawzia¹²³⁴

Affiliation:

1. INSERM, UMR 1170, Gustave Roussy, Villejuif, France

2. University Paris Diderot, Paris, France

3. University Paris-Sud 11, Villejuif, France

4. Gustave Roussy, Villejuif, France

5. Kyoto University, Graduate School of Pharmaceutical Sciences, Kyoto, Japan

6. Equipe labellisée Ligue Nationale contre le Cancer, UMR 1170, Institut Gustave Roussy, Villejuif, France

7. Grex, Laboratoire d’Excellence, Paris, France

8. Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CXCR4-enriched T regulatory cells preferentially home to bone marrow and resolve inflammation;iScience;2024-09

2. Unravelling the CXCL12/CXCR4 Axis in breast cancer: Insights into metastasis, microenvironment interactions, and therapeutic opportunities;Human Gene;2024-05

3. Chemokines in Cartilage Regeneration and Degradation: New Insights;International Journal of Molecular Sciences;2023-12-27

4. Pharmacotherapeutic advances for splenomegaly in myelofibrosis;Expert Opinion on Pharmacotherapy;2023-03-19

5. Correlations Between the Expression of Stromal Cell Activation Related Biomarkers, L-NGFR, Phospho-ERK1-2 and CXCL12, and Primary Myelofibrosis Progression;Pathology and Oncology Research;2022-03-14